Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,823 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine

NCT00873912
Conditions
Healthy
Interventions
Monovalent influenza virus vaccine, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Interventions
Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Placebo, Folic acid 400 -1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg
Drug · Biological · Dietary Supplement
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more
Completed Not applicable Interventional Results available

Efficacy of Open Label Placebo in Children With FGIDs

NCT02389998
Conditions
Functional Abdominal Pain, Functional Dyspepsia, Irritable Bowel Syndrome, Functional Gastrointestinal Disorders
Interventions
Placebo Suspension, Hyoscyamine
Other · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab, Placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
50
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 41 more
Completed Phase 2 Interventional Results available

A New Oral Treatment For Type II Diabetes Mellitus

NCT00111800
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, DEN 2.5 mg, DEN 7.5 mg, DEN 15 mg, DEN 30 mg, DEN 45 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
36
States / cities
Long Beach, California • Pasadena, California • Denver, Colorado + 32 more
Conditions
Chronic Hepatitis B
Interventions
ACH126, 433
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Pasadena, California + 8 more
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, DT120
Other · Drug
Lead sponsor
Definium Therapeutics US, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
34
States / cities
Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more
Conditions
Anaemia
Interventions
GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Rheumatoid Arthritis
Interventions
fostamatinib, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
30
States / cities
Huntsville, Alabama • Huntington Beach, California • Santa Maria, California + 27 more
Conditions
Thrombocytopenia Associated With Liver Disease
Interventions
avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more
Completed Not applicable Interventional Results available

Escitalopram Treatment of Night Eating Syndrome

NCT00636649
Conditions
Night Eating Syndrome
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Durham, North Carolina
Terminated Phase 2 Interventional Results available

Vitamin E for NASH Treatment in HIV Infected Individuals

NCT03669133
Conditions
NAFLD, NASH - Nonalcoholic Steatohepatitis, HIV Infections
Interventions
Vitamin E, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Conditions
Glaucoma
Interventions
ASP2767, Sham ASP2767, Prophylactic Regimen A, Prophylactic Regimen B, Placebo for prophylactic regimen
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
End Stage Renal Disease
Interventions
paricalcitol capsules
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
22
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 18 more
Conditions
Nasal Polyps, Chronic Rhinosinusitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
Completed Not applicable Interventional Accepts healthy volunteers

Skin Refrigerant to Reduce the Pain Associated With IV Insertion

NCT02499965
Conditions
Pain
Interventions
Ethyl Chloride Topical Aerosol Anesthetic, Nature's Tears Sterile Water
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Conditions
Obesity
Interventions
MBX 4291, Placebo
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Doral, Florida • Lexington, Kentucky • Kansas City, Missouri + 1 more
Conditions
Solid Tumors
Interventions
E7080, Comparator Drug, Comparator Drug: Sorafenib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Torrance, California • Chicago, Illinois • Detroit, Michigan
Completed Not applicable Interventional Accepts healthy volunteers

Analgesic Properties of Oral Sucrose During Immunizations

NCT00446875
Conditions
Procedural Pain
Interventions
Administration of oral Sucrose, Administration of oral Placebo
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
3 Months to 11 Months
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Healthy, Type 2 Diabetes Mellitus (T2DM)
Interventions
Tirzepatide, Placebo, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
South Miami, Florida
Conditions
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Interventions
Casdatifan, Cabozantinib, Placebo
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
46
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 40 more
Conditions
Healthy
Interventions
HEPLISAV and/or Placebo, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years to 70 Years
Enrollment
2,452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
29
States / cities
Huntsville, Alabama • San Diego, California • Santa Ana, California + 26 more
Conditions
Knee Osteoarthritis (Knee OA), Chronic Pain, Chronic Knee Pain
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Benedict Alter
Other
Eligibility
45 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Weight Loss With Risedronate for Bone Health

NCT03411902
Conditions
Bariatric Surgery Candidate, Bone Loss, Weight Loss
Interventions
Risedronate Sodium 150 MG, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina